Pulmonary sarcoid-like granulomatosis during etanercept treatment for inflammatory arthritis: A case series and literature review

References

• Broos CE, van Nimwegen M, Hoogsteden HC, Hendriks RW, Kool M, van den Blink B. Van den Blink B. Granuloma formation in pulmonary sarcoidosis. Front Immunol. 2013;4(DEC):437–439. doi:10.3389/fimmu.2013.00437
   Google Scholar
• Hunninghake G, Costabel U, Ando M. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ER. Am J Respir Crit Care Med. 1999;160(2):736–755. doi:10.1164/ajrccm.160.2.ats4-99.
   Google Scholar
• Yousem SA, Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Mod Pathol. 2005;18(5):651–655. doi:10.1038/modpathol.3800333.
   Google Scholar
• Sim JK, Lee SY, Shim JJ, Kang KH. Pulmonary sarcoidosis induced by adalimumab: A case report and literature review. Yonsei Med J. 2016;57(1):272–273. doi:10.3349/ymj.2016.57.1.272.
   Google Scholar
• Daïen CI, Monnier A, Claudepierre P, Club Rhumatismes et Inflammation (CRI), et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford)). 2009;48(8):883–886. doi:10.1093/rheumatology/kep046.
   Google Scholar
• Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series . J Rheumatol. 2009;36(11):2421–2427. doi:10.3899/jrheum.090030.
   Google Scholar
• Chopra R, Chaudhary N, Kay J. Relapsing polychondritis. Rheum Dis Clin North Am. 2013;39(2):263–276. doi:10.1016/j.rdc.2013.03.002.
   Google Scholar
• Koda K, Toyoshima M, Nozue T, Suda T. Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature. Intern Med. 2020;59(16):2015–2021. doi:10.2169/internalmedicine.4275-19.
   Google Scholar
• Michaud A, Vis D, Robertson HL, Weatherald J. Pulmonary Sarcoid-like Granulomatosis During TNF-⍺ inhibition: a scoping review. Poster Presented at the European Respiratory Society International Congress 2020, Austria, Sept 7-9, 2020. Abstract retrieved from <https://ers-program.key4events.com/prod/v2/front/program/?e=259>.
   Google Scholar
• Van Der Stoep D, Braunstahl GJ, Van Zeben J, Wouters J. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. J Rheumatol. 2009;36(12):2847–2848. doi:10.3899/jrheum.090307.
   Google Scholar
• Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 2005;53(4):618–620. doi:10.1002/art.21336.
   Google Scholar
• Vigne C, Tebib JG, Pacheco Y, Coury F. Sarcoidosis: An underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine. 2013;80(1):104–107. doi:10.1016/j.jbspin.2012.05.001.
   Google Scholar
• Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. 1999;16(1):24–31.
   Google Scholar
• Shin J, Kim D. Development of sarcoidosis during anti-TNF-α treatment: what is the mechanism? Clin Exp Rheumatol. 2009;27(6):1054.
   Google Scholar
• Drent M, van den Berg R, Haenen G, Wouters E, Bast A, Va den Berg H. NF-kappaB activation in sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. 2001;18(1):50–56.
   Google Scholar
• Jany B, Betz R, Schreck R. Activation of the transcription factor NF-kappa B in human tracheobronchial epithelial cells by inflammatory stimuli . Eur Respir J. 1995;8(3):387–391. In: Vol European Respiratory Society;doi:10.1183/09031936.95.08030387.
   Google Scholar
• Lawrence T, Gilroy D, Colville-Nash P, Willoughby D. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med. 2001;7(12):1291–1297. doi:10.1038/nm1201-1291.
   Google Scholar
• Toussirot É, Pertuiset É, Kantelip B, Wendling D. Sarcoidosis Occuring during Anti-TNF-α Treatment for Infl Ammatory Rheumatic Diseases: Report of Two Cases. Clin Exp Rheumatol. 2008;26:471–475.
   Google Scholar
• Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438–449. doi:10.1378/chest.14-1120.
   Google Scholar
• Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183(11):1524–1530. doi:10.1164/rccm.201010-1679OC.
   Google Scholar
• Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest. 2018;153(1):105–113. doi:10.1016/j.chest.2017.07.008.
   Google Scholar
• Patterson KC, Chen ES. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest. 2018;153(6):1432–1442. doi:10.1016/j.chest.2017.11.030.
   Google Scholar
• Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-Induced Sarcoidosis-Like Reactions. Chest. 2018;154(3):664–677. doi:10.1016/j.chest.2018.03.056.
   Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301(2):418–426. doi:10.1124/jpet.301.2.418.
   Google Scholar
• Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum. 2005;34(5 Suppl1):34–38. doi:10.1016/j.semarthrit.2005.01.009.
   Google Scholar
• Baughman RP, Drent M, Kavuru M, Sarcoidosis Investigators, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802. doi:10.1164/rccm.200603-402OC.
   Google Scholar
• Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–185. doi:10.1378/chest.124.1.177.
   Google Scholar